There is a useful book to be written about the rise of anti-obesity drugs such as Ozempic, but this flawed account is not it
In the last couple of years, there has been a healthcare revolution. Semaglutide, a drug initially prescribed for diabetes under the name Ozempic, has been shown to reduce obesity dramatically, and repackaged for that use as Wegovy. Other drugs have since been approved.
It’s a big deal. More than half of US and British adults are overweight or obese, and there are few really effective treatments: prescribing dieting is all but useless. As a result, sales have been astronomical. Ozempic’s manufacturer, Novo Nordisk, is now the most valuable company in Europe.
